Safety of Contrast Agent Use During Stress Echocardiography. A 4-Year Experience From a Single-Center Cohort Study of 26,774 Patients

Sahar S. Abdelmoneim, Mathieu Bernier, Christopher G. Scott, Abhijeet Dhoble, Sue Ann C Ness, Mary E. Hagen, Stuart Moir, Robert B. McCully, Patricia Pellikka, Sharon L. Mulvagh

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Objectives: We evaluated the short- and long-term safety of contrast agents during stress echocardiography (SE). Background: Concerns about contrast agent safety led to revised recommendations for product use in the U.S. Methods: We studied 26,774 patients who underwent SE between November 1, 2003, and December 31, 2007. The 10,792 patients who comprised the contrast cohort received second-generation perfluorocarbon-based agents for left ventricular opacification during SE. The noncontrast cohort comprised 15,982 patients who had their first SE in the same period but without contrast agents. Short-term (≤72 h and ≤30 days) and long-term (up to 4.5 years) end points were death and myocardial infarction (MI). Cox regression models were used. Immediate contrast agent-related adverse effects were also reported. Results: The contrast cohort had older patients (mean [SD] age, 65.8 [12.1] years vs. 62.6 [14.1] years; p < 0.001), a higher percentage of males (57.4% vs. 52.8%, p < 0.001), and higher-risk patients compared with the noncontrast cohort. In addition, dobutamine SE patients had greater cardiac risk than exercise SE patients. Abnormal SE findings in patients who received contrast agents were more frequent (32.4% vs. 27.9%, p < 0.001). The 2 cohorts had no statistical difference in the incidence of short-term events (death and MI). Within 72 h, 1 patient in the contrast cohort and 2 patients in the noncontrast cohort died (p = 0.54); 3 in the contrast cohort and 7 in the noncontrast cohort had MI (p = 0.92). Within 30 days, 37 patients (0.34%) in the contrast cohort and 57 patients (0.36%) in the noncontrast cohort died (p = 0.85); 17 patients (0.16%) in the contrast cohort and 16 patients (0.10%) in the noncontrast cohort had MI (p = 0.19). Adjusted hazard ratios were not different between cohorts for death (0.99; 95% confidence interval: 0.88 to 1.11) or MI (0.99; 95% confidence interval: 0.80 to 1.22). Conclusions: The use of contrast agents during SE was not associated with an increased short-term or long-term risk of death or MI.

Original languageEnglish (US)
Pages (from-to)1048-1056
Number of pages9
JournalJACC: Cardiovascular Imaging
Volume2
Issue number9
DOIs
StatePublished - Sep 2009

Fingerprint

Stress Echocardiography
Contrast Media
Cohort Studies
Safety
Myocardial Infarction
Confidence Intervals
Fluorocarbons
Proportional Hazards Models

Keywords

  • contrast agent safety
  • echocardiography
  • ultrasonography

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Radiology Nuclear Medicine and imaging

Cite this

Abdelmoneim, S. S., Bernier, M., Scott, C. G., Dhoble, A., Ness, S. A. C., Hagen, M. E., ... Mulvagh, S. L. (2009). Safety of Contrast Agent Use During Stress Echocardiography. A 4-Year Experience From a Single-Center Cohort Study of 26,774 Patients. JACC: Cardiovascular Imaging, 2(9), 1048-1056. https://doi.org/10.1016/j.jcmg.2009.03.020

Safety of Contrast Agent Use During Stress Echocardiography. A 4-Year Experience From a Single-Center Cohort Study of 26,774 Patients. / Abdelmoneim, Sahar S.; Bernier, Mathieu; Scott, Christopher G.; Dhoble, Abhijeet; Ness, Sue Ann C; Hagen, Mary E.; Moir, Stuart; McCully, Robert B.; Pellikka, Patricia; Mulvagh, Sharon L.

In: JACC: Cardiovascular Imaging, Vol. 2, No. 9, 09.2009, p. 1048-1056.

Research output: Contribution to journalArticle

Abdelmoneim, SS, Bernier, M, Scott, CG, Dhoble, A, Ness, SAC, Hagen, ME, Moir, S, McCully, RB, Pellikka, P & Mulvagh, SL 2009, 'Safety of Contrast Agent Use During Stress Echocardiography. A 4-Year Experience From a Single-Center Cohort Study of 26,774 Patients', JACC: Cardiovascular Imaging, vol. 2, no. 9, pp. 1048-1056. https://doi.org/10.1016/j.jcmg.2009.03.020
Abdelmoneim, Sahar S. ; Bernier, Mathieu ; Scott, Christopher G. ; Dhoble, Abhijeet ; Ness, Sue Ann C ; Hagen, Mary E. ; Moir, Stuart ; McCully, Robert B. ; Pellikka, Patricia ; Mulvagh, Sharon L. / Safety of Contrast Agent Use During Stress Echocardiography. A 4-Year Experience From a Single-Center Cohort Study of 26,774 Patients. In: JACC: Cardiovascular Imaging. 2009 ; Vol. 2, No. 9. pp. 1048-1056.
@article{640bb3f4130f42d4b65b22f3d7f5b944,
title = "Safety of Contrast Agent Use During Stress Echocardiography. A 4-Year Experience From a Single-Center Cohort Study of 26,774 Patients",
abstract = "Objectives: We evaluated the short- and long-term safety of contrast agents during stress echocardiography (SE). Background: Concerns about contrast agent safety led to revised recommendations for product use in the U.S. Methods: We studied 26,774 patients who underwent SE between November 1, 2003, and December 31, 2007. The 10,792 patients who comprised the contrast cohort received second-generation perfluorocarbon-based agents for left ventricular opacification during SE. The noncontrast cohort comprised 15,982 patients who had their first SE in the same period but without contrast agents. Short-term (≤72 h and ≤30 days) and long-term (up to 4.5 years) end points were death and myocardial infarction (MI). Cox regression models were used. Immediate contrast agent-related adverse effects were also reported. Results: The contrast cohort had older patients (mean [SD] age, 65.8 [12.1] years vs. 62.6 [14.1] years; p < 0.001), a higher percentage of males (57.4{\%} vs. 52.8{\%}, p < 0.001), and higher-risk patients compared with the noncontrast cohort. In addition, dobutamine SE patients had greater cardiac risk than exercise SE patients. Abnormal SE findings in patients who received contrast agents were more frequent (32.4{\%} vs. 27.9{\%}, p < 0.001). The 2 cohorts had no statistical difference in the incidence of short-term events (death and MI). Within 72 h, 1 patient in the contrast cohort and 2 patients in the noncontrast cohort died (p = 0.54); 3 in the contrast cohort and 7 in the noncontrast cohort had MI (p = 0.92). Within 30 days, 37 patients (0.34{\%}) in the contrast cohort and 57 patients (0.36{\%}) in the noncontrast cohort died (p = 0.85); 17 patients (0.16{\%}) in the contrast cohort and 16 patients (0.10{\%}) in the noncontrast cohort had MI (p = 0.19). Adjusted hazard ratios were not different between cohorts for death (0.99; 95{\%} confidence interval: 0.88 to 1.11) or MI (0.99; 95{\%} confidence interval: 0.80 to 1.22). Conclusions: The use of contrast agents during SE was not associated with an increased short-term or long-term risk of death or MI.",
keywords = "contrast agent safety, echocardiography, ultrasonography",
author = "Abdelmoneim, {Sahar S.} and Mathieu Bernier and Scott, {Christopher G.} and Abhijeet Dhoble and Ness, {Sue Ann C} and Hagen, {Mary E.} and Stuart Moir and McCully, {Robert B.} and Patricia Pellikka and Mulvagh, {Sharon L.}",
year = "2009",
month = "9",
doi = "10.1016/j.jcmg.2009.03.020",
language = "English (US)",
volume = "2",
pages = "1048--1056",
journal = "JACC: Cardiovascular Imaging",
issn = "1936-878X",
publisher = "Elsevier Inc.",
number = "9",

}

TY - JOUR

T1 - Safety of Contrast Agent Use During Stress Echocardiography. A 4-Year Experience From a Single-Center Cohort Study of 26,774 Patients

AU - Abdelmoneim, Sahar S.

AU - Bernier, Mathieu

AU - Scott, Christopher G.

AU - Dhoble, Abhijeet

AU - Ness, Sue Ann C

AU - Hagen, Mary E.

AU - Moir, Stuart

AU - McCully, Robert B.

AU - Pellikka, Patricia

AU - Mulvagh, Sharon L.

PY - 2009/9

Y1 - 2009/9

N2 - Objectives: We evaluated the short- and long-term safety of contrast agents during stress echocardiography (SE). Background: Concerns about contrast agent safety led to revised recommendations for product use in the U.S. Methods: We studied 26,774 patients who underwent SE between November 1, 2003, and December 31, 2007. The 10,792 patients who comprised the contrast cohort received second-generation perfluorocarbon-based agents for left ventricular opacification during SE. The noncontrast cohort comprised 15,982 patients who had their first SE in the same period but without contrast agents. Short-term (≤72 h and ≤30 days) and long-term (up to 4.5 years) end points were death and myocardial infarction (MI). Cox regression models were used. Immediate contrast agent-related adverse effects were also reported. Results: The contrast cohort had older patients (mean [SD] age, 65.8 [12.1] years vs. 62.6 [14.1] years; p < 0.001), a higher percentage of males (57.4% vs. 52.8%, p < 0.001), and higher-risk patients compared with the noncontrast cohort. In addition, dobutamine SE patients had greater cardiac risk than exercise SE patients. Abnormal SE findings in patients who received contrast agents were more frequent (32.4% vs. 27.9%, p < 0.001). The 2 cohorts had no statistical difference in the incidence of short-term events (death and MI). Within 72 h, 1 patient in the contrast cohort and 2 patients in the noncontrast cohort died (p = 0.54); 3 in the contrast cohort and 7 in the noncontrast cohort had MI (p = 0.92). Within 30 days, 37 patients (0.34%) in the contrast cohort and 57 patients (0.36%) in the noncontrast cohort died (p = 0.85); 17 patients (0.16%) in the contrast cohort and 16 patients (0.10%) in the noncontrast cohort had MI (p = 0.19). Adjusted hazard ratios were not different between cohorts for death (0.99; 95% confidence interval: 0.88 to 1.11) or MI (0.99; 95% confidence interval: 0.80 to 1.22). Conclusions: The use of contrast agents during SE was not associated with an increased short-term or long-term risk of death or MI.

AB - Objectives: We evaluated the short- and long-term safety of contrast agents during stress echocardiography (SE). Background: Concerns about contrast agent safety led to revised recommendations for product use in the U.S. Methods: We studied 26,774 patients who underwent SE between November 1, 2003, and December 31, 2007. The 10,792 patients who comprised the contrast cohort received second-generation perfluorocarbon-based agents for left ventricular opacification during SE. The noncontrast cohort comprised 15,982 patients who had their first SE in the same period but without contrast agents. Short-term (≤72 h and ≤30 days) and long-term (up to 4.5 years) end points were death and myocardial infarction (MI). Cox regression models were used. Immediate contrast agent-related adverse effects were also reported. Results: The contrast cohort had older patients (mean [SD] age, 65.8 [12.1] years vs. 62.6 [14.1] years; p < 0.001), a higher percentage of males (57.4% vs. 52.8%, p < 0.001), and higher-risk patients compared with the noncontrast cohort. In addition, dobutamine SE patients had greater cardiac risk than exercise SE patients. Abnormal SE findings in patients who received contrast agents were more frequent (32.4% vs. 27.9%, p < 0.001). The 2 cohorts had no statistical difference in the incidence of short-term events (death and MI). Within 72 h, 1 patient in the contrast cohort and 2 patients in the noncontrast cohort died (p = 0.54); 3 in the contrast cohort and 7 in the noncontrast cohort had MI (p = 0.92). Within 30 days, 37 patients (0.34%) in the contrast cohort and 57 patients (0.36%) in the noncontrast cohort died (p = 0.85); 17 patients (0.16%) in the contrast cohort and 16 patients (0.10%) in the noncontrast cohort had MI (p = 0.19). Adjusted hazard ratios were not different between cohorts for death (0.99; 95% confidence interval: 0.88 to 1.11) or MI (0.99; 95% confidence interval: 0.80 to 1.22). Conclusions: The use of contrast agents during SE was not associated with an increased short-term or long-term risk of death or MI.

KW - contrast agent safety

KW - echocardiography

KW - ultrasonography

UR - http://www.scopus.com/inward/record.url?scp=70149086779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70149086779&partnerID=8YFLogxK

U2 - 10.1016/j.jcmg.2009.03.020

DO - 10.1016/j.jcmg.2009.03.020

M3 - Article

C2 - 19761981

AN - SCOPUS:70149086779

VL - 2

SP - 1048

EP - 1056

JO - JACC: Cardiovascular Imaging

JF - JACC: Cardiovascular Imaging

SN - 1936-878X

IS - 9

ER -